Analyst Conference Summaries

Biotechnology Investor Aids


conference date: not scheduled

Bioverativ Should have a Strong Launch [January 10, 2017 @ Seeking Alpha]

Note: BIVV should start trading on February 1, 2017. Prior to that it will pre-trade as BIVV WI or BIVVV.



Bioverativ (BIVV) is a commercial-stage biotechnology company specializing in hemophilia therapies and developing therapies for other blood disorders. It was spun off from Biogen (BIIB).

Bioverativ web site



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2017 William P. Meyers